New startup ideas · Health and bio · Healthcare and bio
startup idea
Corpus Bio
The pooled experiment exchange that teaches drug-discovery models what failed.
Corpus Bio sells pharma and biotech R&D organizations a subscription platform that captures every wet-lab experiment - including the roughly 90 percent that fail and never leave the notebook - in a structured, model-readable format.
- Software subscription
- Enterprise
- $100B+ market
- Creates a new category
- Global from day one
4/5
venture judge
6
similar startups, last 2 years (11 all-time)
97%
of 4 nearest real companies still alive
yes
8 matching federal grants and programs
Direction supported by government programs and grants
Scorecard
One score that balances how trendy the idea is, the demand for it and its potential for 100x, with competition measured relative to every other idea in the catalog. Recent startup trends first, government priorities second.
89
Idea Score, 0-100 · raw 54.3 x 1.64
Active
competition: more crowded than 56% of ideas · headwind x0.72
+4.3
government priorities, secondary (70 matching grants)
Trend
77
Is the wave forming now? 2025-26 entrants vs 2023-24, rounds since 2025, the sector's live-batch direction, the 2026 trend analyst.
- Entrants 2025-26 vs 2023-24 (similar companies)90
- Rounds announced 2025+ in the sector68
- Sector direction (live batch)100
- 2026 trend analyst50
Demand
52
Does anyone want it? YC's current RFS, companies already paid for something similar, the operator judge, founders' yes-rate in decks, readers who would run the test.
- YC asks for it (current RFS: idea / sector)30
- Someone already pays (similar companies, recent / all-time)100
- Operator judge: real pain25
100x potential
84
Can it return a fund? The venture judge (double weight), market-size and moat axes, neighbours still alive, the technologist judge.
- Venture judge75
- Market size axis100
- Moat axis100
- Neighbours still alive81
- Technologist judge75
Score = 100 x cbrt(Trend x Demand x 100x) x (1 - 0.5 x crowding) + government bonus (max 5), calibrated so the 95th-percentile idea scores 90 (order never changes). A geometric mean: a weak pillar cannot be papered over. Percentiles are among the 272 ideas in the catalog; the terms matched were pooled, experiment, exchange, teaches, drug-discovery, models, failed, corpus.
The idea in full
- What
- Corpus Bio sells pharma and biotech R&D organizations a subscription platform that captures every wet-lab experiment - including the roughly 90 percent that fail and never leave the notebook - in a structured, model-readable format. Members contribute anonymized assay outcomes to a shared corpus and in return get predictive priors trained on the pooled data: which constructs express, which assays are artifact-prone, which conditions waste a week. Distribution runs through lab instrument vendors and CROs who bundle the capture layer; the software makes no clinical claims and faces no regulator.
- Why now
- 'Drug discovery' is the cluster's most crowded phrase at 5 companies, and the S26/X26 batches (Rasyn's general intelligence for chemistry, WonderTx's extrapolative AI, Omanta's research lab for one) are all model builders starved for exactly the experimental data no one shares - while the graveyard's Great Bay Bio died attacking 'long timelines, high costs, and low success rates' with models alone. The data layer under the crowd is empty.
- Wedge: first customer and entry point
- Ten venture-backed biotechs on the same instrument vendor's channel, starting with protein-expression outcomes - a narrow assay class where pooled failure data pays back within one quarter of avoided repeats.
- Path to 100x
- Global pharma R&D spend runs in the hundreds of billions a year, and a platform whose priors reliably kill doomed experiments early prices against that spend, not against software budgets. The exchange compounds like a network, not a database: every new member's failures improve every other member's models, so the first pool to reach critical mass becomes impossible to leave and unattractive to duplicate, which is how a new pre-competitive data category gets exactly one winner.
- Ceiling
- If the big instrument makers or a pharma consortium stand up a good-enough shared repository themselves, Corpus is reduced to a capture-tooling vendor without the pool that carries the value.
- Closest real companies, as the generator saw them
- Rasyn, WonderTx, and Atlas Discovery build predictive models and would be Corpus customers, not rivals; Omanta automates a single lab rather than pooling across labs; none operates a cross-company exchange.
- Main risk
- Pharma legal departments refuse to contribute even anonymized negative data, leaving the pool too shallow for the priors to beat each company's internal baseline.
Five judges
Each judge scores every idea in the catalog with a named rubric; the venture judge decides whether a card is shown at all (4-5 is venture-grade).
Venture investor
4/5
Pooled failure data prices against hundreds of billions of R&D spend, and every member's failures make the pool harder to leave.
Bootstrapper
3/5
Software margins and a one-quarter payback on protein-expression repeats, but pharma legal review makes each contributing member a slow sale.
Operator
2/5
The product requires pharma legal to share failed-experiment data across competitors, which is the whole industry moving before value appears.
Technologist
4/5
Structuring the 90 percent of experiments that fail into model-readable priors is hard capture engineering whose value grows with every member's contributions.
Risk
3/5
Unregulated with no clinical claims, but distribution depends on instrument vendors and CROs who are also the most likely consortium competitor.
trends
3/5
Shares the real 2025-2026 data-scarcity shift behind the model-builder boom, but pharma legal resistance to pooling was equally blocking in 2023.
Similar startups in the directory
Companies whose pitch matches most of the idea's terms (pooled, experiment, exchange, teaches, drug-discovery, models, failed, corpus): 11 all-time, 6 from the last two years. Same matching as Idea Check.
Host a Poker Club and Make Money
Insurance risk layer for physical AI
Large-scale real-world robot & human data for embodied AI
Elnora is an AI co-pilot for biomedical lab protocols that learns from every experiment to accelerate drug discovery.
Reimagining how Machines Learn
AI powered holistic intelligence and workflow automation suite for Procurement & Supply Chain (P2P, S2C)
Recover failed subscription payments to increase retention and LTV
Developer of an online sports leagues and tournaments management application designed to track individual players' stats. The company's platform follows a multiple-tier revenue model based on subscriptions, commissions, advertising and monetization of big data, enabling customers to get a big enough pool of players, and enough data, to begin their scouting activities.
Foundation models and autonomous chambers for plant biology
AI-powered assistant for personal finances.
Class is a connection between people, the value of money, time and things.
The generator's reference companies
Real companies the model named as closest when it wrote the card, with their fate. A check mark is a company the radar could verify in its directory.
Public money in this direction
US federal grants, SBIR/STTR awards and open opportunities from the radar's public-money feed, matched to the idea's terms; the sector totals give the context.
8
grants and programs matching the idea
1127
startup-relevant grants in Healthcare and bio
$590M
awarded in the sector, tracked
130
opportunities open now in the sector
- I-Corps: Translation potential of accurate acoustic digital twins for complex real-world environmentsawardhigh relevance
National Science Foundation · I-Corps · $50K · posted 2026-08-20
- I-Corps: Translation Potential of a Hybrid Quantum-Classical Drug Discovery Platformawardhigh relevance
National Science Foundation · TIP-CHIPS KTA-3 Quantum · $50K · posted 2026-08-17
- InVitreON: A compact and integrated platform for long-term neuronal culture incubation, recording and closed-loop stimulationawardhigh relevance
NIH / NIMH · SBIR phase I · $457K · posted 2026-08-01
National Science Foundation · CSR-Computer Systems Research · $777K · posted 2026-07-27
- A Novel Human Intestinal Organoid Platform with Peristaltic Function for Drug Discovery and Pre-Clinical Testing in GI Motility Disordersawardhigh relevance
NIH / NCATS · SBIR phase I · $350K · posted 2026-07-15
NIH / NEI · SBIR phase II · $1M · posted 2025-09-30
- Novel Vaginal Speculum for Decreased Patient Pain and Enhanced Provider Functionality in Outpatient Reproductive Careawardhigh relevance
NIH / NICHD · SBIR phase I · $270K · posted 2025-09-15
- Standardizing COA Administration with AI Technology: Ensuring Consistency and Accuracy in Clinical End Pointsawardhigh relevance
NIH / NIMH · SBIR phase I · $447K · posted 2025-09-01
Market signal
What the radar sees in Healthcare and bio: new companies by cohort year, the forming YC batch, and outcomes since the February snapshot.
Healthcare and bio · 130 → 118 → 216 → 173 → 71 new companies 2022 → 2026 · 92% aliveYC S26: 14 in this cluster, 6% of the batch (was 4% in X26) (F26 is still forming: 21 listed)Since February, of 444 YC companies here: 4 acquired, 5 shut down, 37 rewrote their pitch
Design attributes
The card is one cell of a designed set: every axis below was chosen before the text was written, and the text had to realize it.
- Buyer
- Enterprise
- Business model
- Software subscription
- Path to 100x
- Creates a new category
- Market size
- $100B+ market
- Capital intensity
- Capital-medium (ops, field teams)
- Speed to revenue
- Revenue in 1-3 years
- Technical depth
- Deep tech: ML, hardware, bio
- Go-to-market
- Partners and channels
- Moat
- Network effects
- Geography
- Global from day one
- Regulation
- Unregulated
- Vibe
- Boring business
Listed under
An idea sits in its own sector and in any sector its text clearly touches.
More ideas like this
Health and bio · Healthcare and bio
Bylaw Health
The licensed medical group behind your API call, in fifty states.
Bylaw Health holds the professional corporations, state clinician licenses, supervision agreements and payer enrollments in every US state, and exposes them as endpoints: create a clinician, attach a supervising physician, enroll a location with a payer, submit an encounter under a compliant entity.
Health and bio · Healthcare and bio
Bayworks
Licensed GMP manufacturing bays for personalized therapies, sold as bookable capacity.
Bayworks builds standardized, FDA-registered cleanroom modules inside hospital systems and partner CDMO sites, then runs a marketplace where drug sponsors book manufacturing slots by the batch instead of signing multi-year suite reservations.
Health and bio · Healthcare and bio
Assaygrid
Predicts which lab runs will fail before reagents are consumed, across every instrument vendor.
Assaygrid connects to the instrument fleet of pharma, biotech and industrial R&D organizations, learns from run telemetry, reagent lots, operator steps and outcomes, and flags runs likely to fail plus the parameter change that fixes them.
Health and bio · Healthcare and bio
Overturn
Agents that fight payer denials for health systems, then sell what wins.
Overturn deploys an agent workforce inside a health system's revenue cycle that reads each denial, pulls the governing payer medical policy, assembles the clinical record and files the appeal, working through existing EHR and clearinghouse integrations rather than new infrastructure.
Health and bio · Healthcare and bio
Labmesh
Agents that design, order and run preclinical experiments across a global lab network.
Labmesh gives a biotech or pharma scientist an agent that takes a hypothesis, decomposes it into assays, prices and routes each assay to a contract lab on its network, tracks samples, and returns structured results with the raw instrument files.
Health and bio · Healthcare and bio
ChartRail
The consented medical-records rail every AI clinic runs on.
An API that lets AI-native care companies pull a patient's complete medical record with verifiable consent, by operating as a qualified participant in the national health information exchange framework and as a registered clearinghouse.
Fictional company written 2026-08-26 from MarkosWeb data; the companies, grants and numbers around it are real and tracked. Treat the idea as a research prompt, not a plan.